iiinova — where your digital self keeps evolving

Dr. Nagla Abdel Karim @naglaakarimmd.bsky.social · 06/04/2026

It is with my greatest pleasure to lead 2 early career development conversations during ASCO 2026 #ASCO26

Dr. Nagla Abdel Karim @naglaakarimmd.bsky.social · 06/09/2025

I am honored to present today 9/6 our oligometastatic subcommittee updates @IASLC #wclc2025 workshop 2:30 PM WS14 From Guidelines to Implementation in NSCLC: Pertinent Considerations of Adherence to Consensus Standards of Care in Clinical Practice Location: Room 09

110

Dr. Nagla Abdel Karim @naglaakarimmd.bsky.social · 18/04/2025

It is a great honor to be nominated for #IASLC Board Elections. I appreciate your consideration to vote and support my nomination.

110

Dr. Nagla Abdel Karim @naglaakarimmd.bsky.social · 22/03/2025

It was a great pleasure to be part of the SCLC panel at “Call to Action” New York Summit.

020

Dr. Nagla Abdel Karim @naglaakarimmd.bsky.social · 16/02/2025

It has been a great pleasure to present “Immunotherapy and Inflammation: Impact on Cardiovascular Health” #ACCCardioOnc! Cardio-Oncology Conference in DC.

020

Dr. Nagla Abdel Karim @naglaakarimmd.bsky.social · 10/02/2025

Stay Tuned for the updates in Thoracic Neuroendocrine Tumors #NETChatter

051

Dr. Nagla Abdel Karim @naglaakarimmd.bsky.social · 21/12/2024

Lung Cancer Alliance in Arabic-Speaking MENA (LCAM). This group brings together experts from diverse specialties in lung cancer management #Arabic_Speaking_MENA

020

Dr. Nagla Abdel Karim @naglaakarimmd.bsky.social · 04/12/2024

On December 4, 2024, the Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca) for adults with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.

061

Dr. Nagla Abdel Karim @naglaakarimmd.bsky.social · 25/11/2024

It was such a great pleasure to present about KRAS, STK11, Low PDL1 challenges and be part of MaTOS24 Masters of Thoracic Oncology.

190

Reposted by Dr. Nagla Abdel Karim

Jarushka Naidoo @drjnaidoo.bsky.social · 16/11/2024

Superb opinion piece on PCI in SCLC: do we need it in the IO era? Key points: - PCI optional in ES SCLC IO trials - MRI surveillance acceptable in non IO era - in LS SCLC, Adriatic showed PCI beneficial in IO & non IO arms #LCSM #MedSky #OncSky www.sciencedirect.com/science/arti...

23913